CD33 and myeloproliferative disorder: In this study, we show that MPN‐initiating NSC reside in a CD34+/CD38− fraction of neoplastic cells and that these MPN NSC exhibit several cytokine receptors and various clinically relevant target antigens and checkpoint molecules, including CD33 and PD‐L1.